NEW DELHI: Bharat Biotech International Ltd has started massive phase 3 clinical trials of its covid-19 ‘Covaxin’ vaccine. The company plans to enroll 26,000 participants in total, making it the first phase 3 efficacy study for a COVID-19 vaccine and the largest efficacy trial ever conducted in India. As part …
Read More »
Protection in patients was achieved seven days after the second of two doses and 28 days after the first, according to preliminary findings. A vaccine developed jointly by Pfizer and BioNTech was 90% effective in preventing Covid-19 infections in ongoing phase 3 trials, the companies announced Monday. Protection in patients …
Read More »
Written by Kaunain Sheriff M | New Delhi | Updated: September 7, 2020 6:56:29 am The candidate vaccine elicited a “strong” immune response in Phases 1 and 2 of clinical trials in 76 people. (AP Photo) Even when the Lancet published the data from the phase 1 and phase 2 …
Read More »